Table 2 The clinical characteristics of the 403 non-small cell lung cancer (NSCLC) patients
Variate | Total | Overall toxicity | Hematological toxicity | Hepatotoxicity | Gastrointestinal toxicity | Responsea | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Grade 0–2 | Grade 3–4 | Grade 0–2 | Grade 3–4 | Grade 0–2 | Grade 3–4 | Grade 0–2 | Grade 3–4 | CR + PR | SD + PD | ||
All | 403 | 268 (66.5) | 135 (33.5) | 308 (76.4) | 95 (23.6) | 348 (86.4) | 55 (13.6) | 368 (91.3) | 35 (8.7) | 115 (29.1) | 280 (70.9) |
Age (years) | |||||||||||
≤55 | 176 (43.7) | 114 (42.5) | 62 (45.9) | 139 (45.1) | 37 (38.9) | 144 (41.4) | 32 (58.2) | 156 (42.4) | 20 (57.1) | 54 (47.0) | 118 (42.1) |
>55 | 227 (56.3) | 154 (57.5) | 73 (54.1) | 169 (54.9) | 58 (61.1) | 204 (58.6) | 23 (41.8) | 212 (57.6) | 15 (42.9) | 61 (53.0) | 162 (57.9) |
Smoking status | |||||||||||
Never | 170 (42.2) | 107 (39.9) | 63 (46.7) | 131 (42.5) | 39 (41.1) | 142 (40.8) | 28 (50.9) | 154 (41.8) | 16 (45.7) | 46 (40.0) | 119 (42.5) |
Ever | 233 (57.8) | 161 (60.1) | 72 (53.3) | 177 (57.5) | 56 (58.9) | 206 (59.2) | 27 (49.1) | 214 (58.2) | 19 (54.3) | 69 (60.0) | 161 (57.5) |
Sex | |||||||||||
Male | 307 (76.2) | 214 (79.9) | 93 (68.9) | 240 (77.9) | 67 (70.5) | 269 (77.3) | 38 (69.1) | 286 (71.7) | 21 (60.0) | 90 (78.3) | 213 (76.1) |
Female | 96 (23.8) | 54 (20.1) | 42 (31.1) | 68 (22.1) | 28 (29.5) | 79 (22.7) | 17 (30.9) | 82 (22.3) | 14 (40.0) | 25 (21.7) | 67 (23.9) |
Eastern cooperative oncology group (ECOG) performance status | |||||||||||
0–1 | 380 (94.3) | 255 (95.2) | 125 (92.6) | 290 (94.2) | 90 (94.7) | 329 (94.5) | 51 (92.7) | 348 (94.6) | 32 (91.4) | 110 (95.7) | 263 (93.9) |
2 | 23 (5.7) | 13 (4.8) | 10 (7.4) | 18 (5.8) | 5 (5.3) | 19 (5.5) | 4 (7.3) | 20 (5.4) | 3 (8.6) | 5 (4.3) | 17 (6.1) |
Histological type | |||||||||||
Adenocarcinoma | 217 (53.8) | 144 (53.7) | 73 (54.1) | 180 (58.4) | 37 (38.9) | 186 (53.4) | 31 (56.4) | 198 (53.8) | 19 (54.3) | 68 (59.1) | 115 (41.1) |
Squamous cell | 186 (46.2) | 124 (46.3) | 62 (45.9) | 128 (41.6) | 58 (61.1) | 162 (46.6) | 24 (43.6) | 170 (46.2) | 16 (45.7) | 47 (40.9) | 165 (58.9) |
TNM stage | |||||||||||
I–II | 9 (2.2) | 7 (2.6) | 2 (1.5) | 7 (2.3) | 2 (2.1) | 9 (2.6) | 0 (0.0) | 8 (2.2) | 1 (2.9) | 2 (1.7) | 7 (2.5) |
III–IV | 394 (97.8) | 261 (97.4) | 133 (98.5) | 301 (97.7) | 93 (97.9) | 339 (97.4) | 55 (100.0) | 360 (97.8) | 34 (97.1) | 113 (98.3) | 273 (97.5) |
Platinum-based drug | |||||||||||
Cisplatin | 333 (82.6) | 222 (82.8) | 111 (82.2) | 255 (82.8) | 78 (82.1) | 284 (81.6) | 49 (89.1) | 302 (82.1) | 31 (88.6) | 99 (86.1) | 229 (81.8) |
Carboplatin | 70 (17.4) | 46 (17.2) | 24 (17.8) | 53 (17.2) | 17 (17.9) | 64 (18.4) | 6 (10.9) | 66 (17.9) | 4 (11.4) | 16 (13.9) | 51 (18.2) |
Chemotherapy regimen | |||||||||||
Platinum-gemcitabine | 196 (48.6) | 119 (44.4) | 77 (57.0) | 131 (42.5) | 65 (68.4) | 168 (48.3) | 28 (50.9) | 179 (48.6) | 17 (48.6) | 73 (63.5) | 120 (42.8) |
Platinum-pemetrexed | 148 (36.7) | 105 (39.2) | 43 (31.9) | 127 (41.2) | 21 (22.1) | 130 (37.4) | 18 (32.7) | 133 (36.1) | 15 (42.8) | 27 (23.5) | 117 (41.8) |
Platinum-paclitaxel | 35 (8.7) | 27 (10.1) | 8 (5.9) | 30 (9.8) | 5 (5.3) | 30 (8.6) | 5 (9.1) | 33 (9.0) | 2 (5.7) | 9 (7.8) | 26 (9.3) |
Platinum-docetaxel | 20 (5.0) | 14 (5.2) | 6 (4.5) | 17 (5.5) | 3 (3.2) | 16 (4.6) | 4 (7.3) | 19 (5.2) | 1 (2.9) | 4 (3.5) | 15 (5.4) |
Platinum-navelbine | 4 (1.0) | 3 (1.1) | 1 (0.7) | 3 (1.0) | 1 (1.0) | 4 (1.1) | 0 (0.0) | 4 (1.1) | 0 (0.0) | 2 (1.7) | 2 (0.7) |